$ONTX In HMA-naïve patients, oral rigosertib at doses of 840 mg or more per day, administered with azacitidine, was associated with an overall response rate of 90% and, importantly, a complete response rate of 34%,” commented Shyamala C. Navada, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine at Mount Sinai in New York.
  • 4
  • 3